耳鼻咽喉科

订阅

MedSci主页 / 所有栏目 / 耳鼻咽喉科

Int Forum Allergy Rhinol：HLA-II基因与过敏性鼻炎的特异性免疫治疗结果相关

2019-08-03 AlexYang MedSci原创

基因鼻炎免疫治疗
关注

治疗效果的关系，并评估了特异的多态性作为AIT受益AR患者生物标记的情况。研究包括了51名接受HDM AIT的中国AR患者。研究发现，等位基因DRB1*04：06； DRB1*14：05与鼻阻塞、鼻痒、眼痒和活动的改善具有正相关关系。相似的，DQB1*03：02：01； DQB1*05：03： 01与鼻阻塞、鼻痒、眼痒、行为问题和鼻症状评分具有正相关关系。 DRB1*03：01； DRB1*04：

治疗效果的关系，并评估了特异的多态性作为AIT受益AR患者生物标记的情况。

研究包括了51名接受HDM AIT的中国AR患者。研究发现，等位基因DRB1*04：06； DRB1*14：05与鼻阻塞、鼻痒、眼痒和活动的改善具有正相关关系。相似的，DQB1*03：02：01； DQB1*05：03： 01与鼻阻塞、鼻痒、眼痒、行为问题和鼻症状评分具有正相关关系。 DRB1*03：01； DRB1*04：06与鼻症状评分具有正相关关系。相反，DRB1*07：01：01； DRB1*11：01与非花粉症状、行为问题和鼻症状呈现负相关关系。

最后，研究人员指出，在HDM敏感的中国AR患者中，HLA-DRB1和HLA-DQB1基因多态性与AIT疗效相关。其中，DRB1*03：01、DRB1*04：06和DQB1*03：02：01以及DQB1*05：03：01也许可以作为有效AIT治疗AR患者的有用的生物标记。

原始出处：

Zhao Y， Zhao Y， Zhang Y et al. HLA-II genes are associated with outcomes of specific immunotherapy for allergic rhinitis. Int Forum Allergy Rhinol. 12 Jul 2019

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047141, encodeId=4e42204e141c0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 07 23:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899317, encodeId=6ca5189931ed4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu May 07 21:09:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329266, encodeId=80081329266ea, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502060, encodeId=74871502060bb, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535932, encodeId=1b2a153593293, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=)]
    2019-09-07 hongbochen

    #过敏性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2047141, encodeId=4e42204e141c0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 07 23:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899317, encodeId=6ca5189931ed4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu May 07 21:09:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329266, encodeId=80081329266ea, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502060, encodeId=74871502060bb, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535932, encodeId=1b2a153593293, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=)]
    2020-05-07 jinweidong

    #特异性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2047141, encodeId=4e42204e141c0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 07 23:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899317, encodeId=6ca5189931ed4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu May 07 21:09:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329266, encodeId=80081329266ea, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502060, encodeId=74871502060bb, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535932, encodeId=1b2a153593293, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=)]
    2019-08-05 膀胱癌

    #ALL#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2047141, encodeId=4e42204e141c0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 07 23:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899317, encodeId=6ca5189931ed4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu May 07 21:09:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329266, encodeId=80081329266ea, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502060, encodeId=74871502060bb, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535932, encodeId=1b2a153593293, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=)]
    2019-08-05 marongnuan

    #HLA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2047141, encodeId=4e42204e141c0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 07 23:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899317, encodeId=6ca5189931ed4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu May 07 21:09:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329266, encodeId=80081329266ea, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502060, encodeId=74871502060bb, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535932, encodeId=1b2a153593293, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Mon Aug 05 12:09:00 CST 2019, time=2019-08-05, status=1, ipAttribution=)]
    2019-08-05 jiadan198786

    #治疗结果#

    0

相关资讯

蛋白与基因齐测，精准与质控护航，BD打造单细胞多组学研究航母

2019年7月25日，由全球领先的医疗技术公司BD（中国）主办的首届单细胞免疫学国际峰会在沪隆重召开，上海市免疫学研究所所长苏冰教授，BD全球首席科学家 Robert Balderas，美国纽约大学副教授 Pratip Chattopadhyay，新加坡 A*STAR 高级首席研究员 Anis Larbi，及国内众多知名免疫学专家齐聚一堂，共话单细胞研究的前沿技术与发展趋势。会

Dev Cell：免疫疗法不起效，原来这么多肿瘤细胞打开了“隐身”基因

自2011年首款免疫检查点抑制剂问世以来，黑色素瘤、乳腺癌、肺癌等多种癌症的患者获得了生的希望，显着提高生存率。遗憾的是，这类免疫治疗并不是对所有癌症患者都有效。以乳腺癌为例，有研究估计，使用免疫检查点抑制剂药物，只有5%~30%的患者从中受益。

Orphanet J Rare Dis：中国特雷切尔·柯林斯综合症家庭中TCOF1病理变异鉴定和听力重建效果研究

特雷切尔·柯林斯综合（TC，OMIM 154500）是一种颅面部发育异常的常染色体疾病，新生儿的发病率为五万分之一。尽管TCOF1、POLR1D和POLR1C已经鉴定是大约90%的TCS患者的致病基因，而8%-11%的患者的致病变异仍旧不清楚。最近，有研究人员阐释了来源于4个家庭的14名临床诊断为TCS患者的分子基础，研究人员使用的是外显子组测序（WES），并利用Sanger测序进行了鉴定。之后，

J Cell Biochem：MicroRNA-140能够通过靶向YES原癌基因1来抑制前列腺癌细胞的侵入和迁移

前列腺癌（PCa）是男性泌尿生殖系统的一种具有侵略性的恶性肿瘤。最近，有研究人员确定了microRNA-140（miR-140）对PCa的影响。研究人员将miR-140或者阴性对照转染到了PCa细胞中，并使用MTT、伤口愈合试验和Transwell试验确定了miR-140在细胞增殖、迁移和浸润中的作用情况。研究人员还利用双荧光素酶报告试验确认了miR-140与YES原癌基因之间的关系。研究发现，m

Int J Pediatr Otorhinolaryngol：非综合征听力损失家庭中MYO15A基因新的纯和变异鉴定

全世界中有数百万的人口遭受听力损失的折磨。先天性耳聋或者语前聋患者中，不少于50%的患者与遗传因子有关，并且具有高度的遗传异质性。到目前为止，尽管数百个基因在非综合征听力损失患者中已经发现，但是仍旧有许多基因或者位点需要去鉴定。最近，有研究人员利用靶标测序和Sanger测序的方法对患有常染色体阴性非综合征听力损失的哈萨克坦血统家庭进行了鉴定。之后，研究人员利用功能和结构研究来预测该新的变异造成的病

Nat Genet：这个基因竟与四种罕见神经退行性疾病都有关

神经退行性疾病一直是医学研究难以攻克的一大疾病，像是阿尔茨海默症、帕金森、癫痫、亨廷顿病等都是我们所熟悉的神经退行性疾病。当然，对于一些罕见的神经退行性疾病科学家也没有放弃。同一种疾病可能是由于不同的基因突变导致的，这就使得许多遗传性疾病治疗变得复杂。如果能够找到其中的共同点，或将为治疗带来新方法。